Apotex Corp. Launches Generic Fertility Treatment Injectable Cetrorelix® in the United States
14 May 2024
Drug Approval
WESTON, Fla., May 14, 2024 /PRNewswire/ - Apotex Corp. announced today the launch of Cetrorelix Acetate for Injection 0.25mg, a generic version of Cetrotide® in the United States.
Cetrorelix Acetate for Injection is a synthetic decapeptide with gonadotrophin-releasing hormone (GnRH) antagonist, indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
"This launch provides American women access to affordable fertility treatments," said Christine Baeder, President, Apotex Corp. "It demonstrates our unwavering focus on meeting patient needs with high-quality medication that is more accessible to everyone."
Please refer to the complete Prescribing information here for information on Warnings and Precautions, Adverse Reactions and Contraindications.
About Apotex Corp.
Apotex Corp. is a US-based company that sells high-quality, affordable and complex medicines to patients in the United States. Headquartered in Weston, Florida, Apotex Corp. and its global affiliates are committed to supplying patients with an integrated portfolio of generic, biosimilar and innovative branded pharmaceutical products.
SOURCE Apotex Corp.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.